Thus, our study provides a rationale for conducting clinical studies to investigate combination therapy with EGFR inhibitors and PD1/PD-L1 axis blocking antibodies especially in EGFR-driven lung cancer with either as a result of sensitizing mutations or overexpression of wild type EGFR. Here, EGFR is linked to lung carcinoma.